NEW YORK, July 14, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of CenturyLink, Inc. (NYSE:CTL) from February 27, 2014 through June 15, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for CenturyLink investors under the federal securities laws.
To join the CenturyLink class action, go to http://rosenlegal.com/cases-1149.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
The complaint alleges that defendants during the Class Period made false and misleading statements and/or failed to disclose that: (1) CenturyLink’s policies allowed its employees to add services or lines to accounts without customer permission, resulting in millions of dollars in unauthorized charges to CenturyLink customers; (2) accordingly, CenturyLink’s revenues were the product of illicit conduct and unsustainable; (3) the foregoing illicit conduct was likely to subject CenturyLink to heightened regulatory scrutiny; and (4) as a result, CenturyLink’s public statements were materially false and misleading at all relevant times.
On June 16, 2017, Bloomberg reported on a lawsuit recently filed by former CenturyLink employee Heidi Heiser alleging that Heiser was fired days after notifying Chief Executive Officer Glen Post of CenturyLink’s high-pressure sales culture that left customers paying millions of dollars for accounts they didn't request. On this news, shares of CenturyLink fell $1.23 per share or over 4% to close at $25.72 per share on June 16, 2017, damaging investors.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 21, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1149.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 



